AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and Rinvoq.

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Tom Lee, Fundstrat Global Advisors managing partner and head of research, appeared on CNBC to talk about his 2025 playbook.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

These 5 companies have not missed on earnings in 5 years. That's an impressive feat with the pandemic hitting in 2020.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...